New drug combo tested for tough leukemia in young adults
NCT ID NCT03571321
Summary
This early-stage study aims to find out if adding the drug ruxolitinib to standard chemotherapy is safe and tolerable for adolescents and young adults (ages 18-40) newly diagnosed with a specific, hard-to-treat type of acute lymphoblastic leukemia (ALL). The main goal is to check for side effects when the drugs are combined. Researchers will also look at whether this combination helps clear the cancer and improves survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Chicago Medical Center
RECRUITINGChicago, Illinois, 60637, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.